101 hits for »HTA «
…Technology Assessment (HTA) regulations. With EURORDIS and EUCOPE at the helm of the initiative, the group is currently focusing on developing concrete policy proposals for the revision of the OMP regulation, developing an operational framework for modulating incentives & policies, and developing proposals to contribute…
…on eligible groups of patients * Understand how HTA and non-HTA payor discussions can benefit from earlier modelling of limited data * See examples of how dashboards of inputs and outputs can help to improve focus on what matters most To register, click this link….
…1200 attendees from pharma, biotech and Payers/HTA’s. Including Evidence, Market Access & Pricing, Rare Diseases, HTA multiple streams and the most burning industry discussions. EUCOPE’s Alexander Natz will be speaking at the event. Register using this link: https://www.terrapinn.com/EPA/EUCOPE **EUCOPE members receive a 50% discount –…
…EU is revising the regulatory and incentive systems for all medicines, including orphan products. The imminent application of the EU HTA Procedure means there will be a new mandatory system for assessing the clinical value of new products for the European market, starting with cancer…
…and we will see how a multi-stakeholder initiative – RWE4Decisions – is tackling those issues. Our special guests include: Karen Facey, Senior Advisor HTA, RWE4Decisions Carlos Martin Saborido, Scientific Officer, Spanish Ministry of Health Alexander Natz, Secretary General, EUCOPE This episode is hosted by EUCOPE’s…
…World Data) to improve access to CGP in the cancer ecosystem. ECGP will evolve funding and P&R frameworks by gathering evidence and aligning stakeholder perspectives on optimal access pathways (e.g. HTA, payer, clinician, pathologist, patient, industry) and identify cross-market learnings on the patient diagnostic journey…
…new treatments to people across Europe. The desire to facilitate rapid access to promising therapies in areas of unmet medical need must be accompanied by education to help payers and health technology assessment (HTA) entities determine the value of these products and make confident decisions…
…focused on in 2024? The European Parliament elections combined with the upcoming implementation of the EU HTA Regulation in 2025 and the revision of the EU Pharmaceutical Legislation and Orphan Medicines Regulation (OMP) make 2024 a transformational year. As a group, we are very focused…
…stakeholders’ evidence needs (for advanced medicinal therapeutic products [ATMPs], for example), stretched healthcare budgets and pressure on pricing. The duration of HTA and price negotiations, which varies across Member States, determines how quickly patients get access to new medicines. The average time to access for…
…collaborative evidence generation – improving the scientific quality of evaluations and ensuring the generation of evidence useful to all actors in the lifecycle of medicines, including HTAs, and pricing and reimbursement authorities; Enable and leverage research and innovation in regulatory science; Enhance collaboration with other…
You are currently viewing a placeholder content from Facebook. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Instagram. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from X. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More Information